FDA Delays Action On MedImmune's Rezield Despite Negative Panel Vote
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency may have needed more time to investigate allegations in a wrongful discharge lawsuit challenging data integrity in a motavizumab surveillance study.
You may also be interested in...
AstraZeneca's Rezield Hits Another Regulatory Wall
FDA's request for another clinical trial before approving MedImmune's Rezield for prevention of respiratory syncytial virus could reflect an advisory committee's recommendations that the company show some advantage over its currently approved RSV agent, Synagis, particularly in sicker children
AstraZeneca's Rezield Hits Another Regulatory Wall
FDA's request for another clinical trial before approving MedImmune's Rezield for prevention of respiratory syncytial virus could reflect an advisory committee's recommendations that the company show some advantage over its currently approved RSV agent, Synagis, particularly in sicker children
AstraZeneca's Rezield Hits Another Regulatory Wall
FDA issues a second "complete response" letter for the respiratory syncytial virus prophylaxis agent, this time seeking a new clinical trial.